153 related articles for article (PubMed ID: 16979660)
1. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
[TBL] [Abstract][Full Text] [Related]
2. Urokinase and its receptors in chronic kidney disease.
Zhang G; Eddy AA
Front Biosci; 2008 May; 13():5462-78. PubMed ID: 18508599
[TBL] [Abstract][Full Text] [Related]
3. Does the urokinase receptor exist in a latent form?
Yuan C; Huang M
Cell Mol Life Sci; 2007 May; 64(9):1033-7. PubMed ID: 17372678
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional interplay among the ligand-binding domains of the urokinase-plasminogen-activator-receptor-associated protein, Endo180.
Rivera-Calzada A; Robertson D; MacFadyen JR; Boskovic J; Isacke CM; Llorca O
EMBO Rep; 2003 Aug; 4(8):807-12. PubMed ID: 12856000
[TBL] [Abstract][Full Text] [Related]
5. Systemic and topical administration of spermidine accelerates skin wound healing.
Ito D; Ito H; Ideta T; Kanbe A; Ninomiya S; Shimizu M
Cell Commun Signal; 2021 Mar; 19(1):36. PubMed ID: 33752688
[TBL] [Abstract][Full Text] [Related]
6. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
[TBL] [Abstract][Full Text] [Related]
7. Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor.
Rullo AF; Fitzgerald KJ; Muthusamy V; Liu M; Yuan C; Huang M; Kim M; Cho AE; Spiegel DA
Angew Chem Int Ed Engl; 2016 Mar; 55(11):3642-6. PubMed ID: 26879524
[TBL] [Abstract][Full Text] [Related]
8. Potential hemostatic compounds targeting urokinase plasminogen activator explored from three Euphorbiaceae species: Euphorbia maculata, Euphorbia humifusa, and Acalypha australis, with bio-affinity ultrafiltration UPLC-MS.
Rakotondrabe TF; Fan M; Hu G; Guo M
Phytochem Anal; 2024 Jan; 35(1):28-39. PubMed ID: 37571866
[TBL] [Abstract][Full Text] [Related]
9. Expression and crystallographic studies of the ligand-binding region of the human endocytic collagen receptor uPARAP.
Yuan C; Huang JH; Liu M; Huang M
Acta Crystallogr F Struct Biol Commun; 2015 Nov; 71(Pt 11):1442-7. PubMed ID: 26527274
[TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase plasminogen activator receptor, platelet aggregation, and carotid plaque thickness in diabetes: A cross-sectional analysis.
Rotbain Curovic V; Tavenier J; Ferreira-Divino LF; Poulsen CG; Houlind MB; Pedersen OB; Urbak L; Hansen TW; Sillesen H; Frimodt-Møller M; Hvas AM; Rossing P
J Diabetes Complications; 2024 Jan; 38(1):108654. PubMed ID: 38042098
[No Abstract] [Full Text] [Related]
11. Soluble Urokinase Receptor and Acute Kidney Injury.
Schley G; Rosen S; Heyman SN
N Engl J Med; 2020 May; 382(22):2167. PubMed ID: 32459935
[No Abstract] [Full Text] [Related]
12. Soluble Urokinase Receptor and Acute Kidney Injury.
Iversen E; Houlind MB; Eugen-Olsen J
N Engl J Med; 2020 May; 382(22):2166-2167. PubMed ID: 32459934
[No Abstract] [Full Text] [Related]
13. Soluble Urokinase Receptor and Acute Kidney Injury.
Schönermarck U; Suttmann Y; Fischereder M
N Engl J Med; 2020 May; 382(22):2166. PubMed ID: 32459933
[No Abstract] [Full Text] [Related]
14. Soluble Urokinase Receptor and Acute Kidney Injury. Reply.
Hayek SS; Leaf DE; Reiser J
N Engl J Med; 2020 May; 382(22):2167-2168. PubMed ID: 32459936
[No Abstract] [Full Text] [Related]
15. Photo-Click-Facilitated Screening Platform for the Development of Hetero-Bivalent Agents with High Potency.
Sun L; Gai Y; McNitt CD; Sun J; Zhang X; Xing W; Li Z; Popik VV; Zeng D
J Org Chem; 2020 May; 85(9):5771-5777. PubMed ID: 32223160
[TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia.
Zahr RS; Rashkin SR; Ruiz MA; Elsherif L; Ren G; Salas G; Ataga KI; Gordeuk VR; Lebensburger J; Zhang X; Saraf SL
Haematologica; 2024 May; ():. PubMed ID: 38695132
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a functional RNA element in the hepatitis C virus core gene.
McMullan LK; Grakoui A; Evans MJ; Mihalik K; Puig M; Branch AD; Feinstone SM; Rice CM
Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2879-84. PubMed ID: 17299041
[TBL] [Abstract][Full Text] [Related]
18. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease.
Zohn IE; De Domenico I; Pollock A; Ward DM; Goodman JF; Liang X; Sanchez AJ; Niswander L; Kaplan J
Blood; 2007 May; 109(10):4174-80. PubMed ID: 17289807
[TBL] [Abstract][Full Text] [Related]
19. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators.
Bartee E; McCormack A; Früh K
PLoS Pathog; 2006 Oct; 2(10):e107. PubMed ID: 17238276
[TBL] [Abstract][Full Text] [Related]
20. Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin.
Pan F; Sun L; Kardian DB; Whartenby KA; Pardoll DM; Liu JO
Nature; 2007 Jan; 445(7126):433-6. PubMed ID: 17230191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
